Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| SMZ-Ost Donauspital | OTHER |
Not provided
Not provided
Not provided
Not provided
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic challenging health systems worldwide.
While there is a clear correlation between oxidative stress markers and the severity of many viral diseases such as hepatitis C, for SARS-CoV clinical data is limited.
The investigators aim at 1.) investigating DNA damage, oxidative stress, inflammation, and aging markers in COVID-19 patients and compare them with age and gender matched healthy controls and patients with influenza; and 2.) investigating all aforementioned parameters during "cytokine storm" via repeated blood sampling.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Covid-19 | Covid-19 patients |
| |
| Influenza | Influenza patients |
| |
| Cotrol | Control group |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | Case-control design, one single investigation |
|
| Measure | Description | Time Frame |
|---|---|---|
| DNA damage | Compare DNA damage (% of DNA in the tail; measured by the comet assay) between hospitalized COVID-19 patients to influenza patients and healthy controls. | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| The investigators will consider further DNA damage parameter | Compare other DNA damage endpoints measured with the comet assay (i.e. tail length, tail moment and damage index) between hospitalized COVID-19 patients to influenza patients and healthy controls. | Baseline |
| The investigators will consider oxidative stress marker |
Not provided
Covid 19 group:
Inclusion Criteria:
Exclusion Criteria:
Control group:
Inclusion criteria:
Exclusion criteria:
children (≤ 18 years) and adults 19-39years
any current or past clinically significant pathology/disease (comorbidity) such as:
Influenza group:
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Covid 19 patients:
Cases after hospital admission.
Influenza:
Cases after confirmed influenza diagnosis
Healthy controls:
Healthy subjects from the general population
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Karl-Heinz Wagner, PhD | Contact | +4314277 | 54930 | karl-heinz.wagner@univie.ac.at |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Klinik Donaustadt | Recruiting | Vienna | 1220 | Austria |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Compare oxidative stress biomarker malondialdehyde, FRAP, GSH, GSSG (all µmol/L) and the ration GSH/GSSG between hospitalized COVID-19 patients to influenza patients and healthy controls. |
| Baseline |
| The investigators will consider inflammatory marker | Compare inflammatory marker Interleukin 1 (IL-1), IL-6, IL-8, IL-10, TNF-alpha (all rfU) and CRP (mg/dl) between hospitalized COVID-19 patients to influenza patients and healthy controls. | Baseline |
| The investigators will consider the phenotypic age marker | Compare the phenotypic age marker between hospitalized COVID-19 patients to influenza patients and healthy controls. | Baseline |
| The investigators will consider RDA and DNA gene expression | Compare RNA and DNA gene expression between hospitalized COVID-19 patients to influenza patients and healthy controls. | Baseline |
| The investigators will consider clinical biochemistry marker | Compare clinical biochemistry (Total cholesterol (mg/dl), LDL-cholesterol (mg/dl), triglycerides (mg/dl), blood glucose (mg/dl), uric acid (mg/dl)) between hospitalized COVID-19 patients to influenza patients and healthy controls. | Baseline |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |